Aspen Sells Asia-Pacific Business to BGH Capital for A$2.37 Billion
Quidah is an online platform that connects investors with curated opportunities and expert insights on Africa’s emerging markets, while offering businesses promotional services, partnership facilitation, and market intelligence to attract capital and grow their operations.
Industries
Aspen Pharmacare Holdings Ltd agreed through subsidiary Aspen Global Incorporated to sell its Asia-Pacific operations excluding China to BGH Capital for A$2.37 billion ($1.59 billion, ZAR 26.5 billion) on a cash- and debt-free basis. The binding agreements cover Australia, New Zealand, Hong Kong, Malaysia, Taiwan, and Philippines pharmaceutical operations, assets, and intellectual property.
The transaction includes Aspen's Dandenong manufacturing facility in Australia. The divested businesses generated 18% of group revenue and 26% of EBITDA for the financial year ended June 2025. Aspen received an unsolicited offer from BGH Capital, which its board evaluated as compelling.
Proceeds will substantially reduce group debt and financing costs, improving balance sheet flexibility. Completion expected Q2 2026 subject to shareholder and regulatory approvals.
Aspen described the divestment as consistent with portfolio simplification while maintaining core therapeutic and regional focus.
